Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A

Summary

The Phase 3 A-LONG and Kids A-LONG studies demonstrated the prolonged half-life of rFVIIIFc compared with rFVIII, and the safety and efficacy of rFVIIIFc in subjects with severe haemophilia A. Eligible subjects from A-LONG and Kids A-LONG continued rFVIIIFc treatment by enrolling in ASPIRE, an ongoing extension study. Based on combined data from the primary studies and ASPIRE interim data, the safety and efficacy of rFVIIIFc in subjects requiring surgery were evaluated. Perioperative dosing regimens were determined by investigators with guidance based on pharmacokinetic data and recommendations from a clinical dosing committee. In addition to dosing frequency, factor consumption, blood loss, transfusions, bleeding episodes, and haemostatic response were assessed. Across studies, 21 subjects underwent 23 evaluable major surgeries, including 19 orthopaedic surgeries; 41 subjects underwent 52 minor surgeries, including 30 dental procedures. No major and 10 minor surgeries were performed in paediatric subjects. Of the major (n = 22) and minor (n = 32) surgeries assessed for haemostatic response, all were rated as excellent or good by the investigator/surgeon. During most major surgeries (95.7 %), haemostasis was maintained with one rFVIIIFc infusion. Blood loss in major surgeries was consistent with similar surgeries in subjects without haemophilia. Across studies, rFVIIIFc was well tolerated; no subject developed an inhibitor.

Keywords

Phase 3 trial - factor VIII - haemophilia A - haemostasis - surgery

• References

• 1 Hermans C, Altisent C, Batorova A. et al. Replacement therapy for invasive procedures in patients with haemophilia: literature review, European survey and recommendations. Haemophilia 2009; 15: 639-658.
• 2 Rudowski WJ, Scharf R, Ziemski JM. Is major surgery in hemophiliac patients safe?. World J Surg 1987; 11: 378-386.
• 3 Valentino LA. Blood-induced joint disease: the pathophysiology of hemophilic arthropathy. J Thromb Haemost 2010; 08: 1895-1902.
• 4 Rodriguez-Merchan EC. Aspects of current management: orthopaedic surgery in haemophilia. Haemophilia 2012; 18: 8-16.
• 5 Makris M. Prophylaxis in haemophilia should be life-long. Blood Transfus 2012; 10: 165-168.
• 6 Mahlangu J, Powell JS, Ragni MV. et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood 2014; 123: 317-325.
• 7 Young G, Mahlangu J, Kulkarni R. et al. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J Thromb Haemost 2015; 13: 967-977.
• 8 Nolan B, Mahlangu J, Perry D. et al. Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A. Haemophilia. 2015 Epub ahead of print.
• 9 International Conference on Harmonisation. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice E6(R1). 1996
• 10 World Medical Association. WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects. 1964
• 11 Srivastava A, Brewer AK, Mauser-Bunschoten EP. et al. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1-e47.
• 12 Prasad N, Padmanabhan V, Mullaji A. Blood loss in total knee arthroplasty: an analysis of risk factors. Int Orthop 2007; 31: 39-44.
• 13 Sinclair JH. Loss of blood following the removal of teeth in normal and hemophilia patients. Oral Surg Oral Med Oral Pathol 1967; 23: 415-420.
• 14 Martinowitz U, Luboshitz J, Bashari D. et al. Stability, efficacy, and safety of continuously infused sucrose-formulated recombinant factor VIII (rFVIII-FS) during surgery in patients with severe haemophilia. Haemophilia 2009; 15: 676-685.
• 15 Menezes S, Manso T, Seifert I. et al. Blood loss in total hip/knee replacement surgery. Eur J Anaesthesiol 2011; 28: 92.
• 16 Nelson CL, Bowen WS. Total hip arthroplasty in Jehovah’s Witnesses without blood transfusion. J Bone Joint Surg Am 1986; 68: 350-353.
• 17 Shapiro AD, Ragni MV, Kulkarni R. et al. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. J Thromb Haemost 2014; 12: 1788-1800.
• 18 Windyga J, Rusen L, Gruppo R. et al. BDDrFVIII (Moroctocog alfa [AF-CC]) for surgical haemostasis in patients with haemophilia A: results of a pivotal study. Haemophilia 2010; 16: 731-739.
• 19 Santagostino E, Lentz SR, Misgav M. et al. Safety and efficacy of turoctocog alfa (NovoEight) during surgery in patients with haemophilia A: results from the multinational guardian clinical trials. Haemophilia 2015; 21: 34-40.
• 20 Scharrer I, Brackmann HH, Sultan Y. et al. Efficacy of a sucrose-formulated recombinant factor VIII used for 22 surgical procedures in patients with severe haemophilia A. Haemophilia 2000; 06: 614-618.
• 21 Negrier C, Shapiro A, Berntorp E. et al. Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: efficacy and safety of Advate in previously treated patients. Thromb Haemost 2008; 100: 217-223.
• 22 Bjorkman S, Oh M, Spotts G. et al. Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. Blood 2012; 119: 612-618.
• 23 van Dijk K, van der Bom JG, Lenting PJ. et al. Factor VIII half-life and clinical phenotype of severe hemophilia A. Haematologica 2005; 90: 494-498.
• 24 Rosencher N, Kerkkamp HE, Macheras G. et al. Orthopedic Surgery Transfusion Hemoglobin European Overview (OSTHEO) study: blood management in elective knee and hip arthroplasty in Europe. Transfusion 2003; 43: 459-469.
• 25 Sommer JM, Moore N, Guffie-Valentine B. et al. Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories. Haemophilia 2014; 20: 294-300.
• 26 Tiefenbacher S, Robinson MM, Ross EL. et al. Comparison of FVIII activity of select novel recombinant FVIII replacement products in commonly used FDAapproved one-stage clot assay systems. Poster presented at: International Society on Thrombosis and Haemostasis (ISTH); 20–25 June 2015; Toronto, Canada. Poster ISTH15ABS-4086.
• 27 Gu JM, Ramsey P, Evans V. et al. Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94–9027) for haemophilia A. Haemophilia 2014; 20: 593-600.